-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk's Wegovy cuts BMI 13.5% in children aged 6 to under 12 in Phase 3 trial

PUBT·11/16/2026 15:07:25
Listen to the news
Novo Nordisk's Wegovy cuts BMI 13.5% in children aged 6 to under 12 in Phase 3 trial
  • Novo Nordisk announced Phase 3 STEP Young results showing Wegovy reduced obesity more than placebo in children aged 6 to under 12.
  • Treatment combined with lifestyle changes improved weight status, with some children no longer classified as having obesity.
  • No unexpected safety concerns emerged; researchers identified no safety concerns affecting growth or pubertal development.
  • Results were presented at ObesityWeek 2026 and published in The New England Journal of Medicine on November 16, 2026.
  • Semaglutide injection remains investigational for children under 12 and is not approved for that age group in the United States.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.